hMAO-B/MB-COMT-IN-1 is a dualMAO-B/MB-COMTinhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD)^[1].

hMAO-B, MB-COMT^[1]

hMAO-B/MB-COMT-IN-1 (compound 3, 50 μM, 24 h) decreases in resazurin reduction in differentiated SH-SY5Y cells^[1].
hMAO-B/MB-COMT-IN-1 (50 μM, 24 h) displays lysosomal toxicity by producing ROS in differentiated SH-SY5Y cells^[1].
hMAO-B/MB-COMT-IN-1 (10 μM, 30 min) displays remarkable cytoprotective effects against t-BHP in differentiated SH-SY5Y cells^[1].
hMAO-B/MB-COMT-IN-1 is predicted to cross the blood-brain barrier (BBB) by passive diffusion, determined by the parallel artificial membrane permeability assay (PAMPA)-BBB kit^[1].

273.33

C₁₆H₁₉NO₃

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.